Luxempart invests in Alphacaps
Context
Luxempart acquired a substantial minority stake in Alphacaps GmbH. The deal is meticulously designed to establish a long-term, highly aligned partnership between the historical owners and the incoming financial sponsor. By providing a flexible capital solution, Luxempart injects fresh momentum into the enterprise, perfectly equipping the incumbent management team with the vital strategic backing and resources required to actively execute their ongoing development roadmap. The primary objective of this new alliance is to massively accelerate the target's expansion within the fast-growing European nutritional supplements market.
Alphacaps, which reported an EBITDA margin of [members only] in 2023, is valued in this transaction at an EV/EBITDA multiple of [members only], to compare with the average observed in the Healthcare & Pharma sector (16.0x in 2023).
-> Deep-dive in Healthcare & Pharma market trends
Target
Alphacaps is a leading full-service contract developer and manufacturer specifically dedicated to the nutritional and food supplements industry. Benefiting from deep sector know-how and state-of-the-art production machinery, the enterprise holds all the required certifications to manufacture a comprehensive variety of high-quality formulations and formats. The firm operates within a rapidly expanding market and heavily differentiates itself through its uncompromising product quality, relentless focus on customer satisfaction, and exceptional agility in rapidly adapting to ever-changing consumer trends. Driven by robust operational fundamentals, the company is ideally positioned to capitalize on structural market growth.
Ent. Value
[members only]
Equity Value
[members only]
Multiples
EV / Revenue
[members only]
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with Luxempart
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 02/2026 | LUXEMPART | KESTREL VISION | FRANCE | Instrumentation & Measurement |
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 11/2023 | ANJAC BEAUTY & HEALTH | STEPHID | FRANCE | CDMO |
| 11/2023 | AMETEK | PARAGON MEDICAL | UNITED STATES | Medical Devices |
| 10/2023 | RESONETICS | NITINOL BUSINESS | UNITED STATES | Medical Devices |
| 08/2023 | OAKLEY CAPITAL INVESTMENTS | LIBERTY DENTAL GROUP | GERMANY | Implants & Prosthetics |
| 08/2023 | CARL ZEISS MEDITEC | D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) | NETHERLANDS | Medical Devices |
| 08/2023 | ATHOS CONSORTIUM | SCHÜLKE | GERMANY | Medical Consumables |
| 07/2023 | ELOS MEDTECH | KLINGEL MEDICAL GROUP | GERMANY | Implants & Prosthetics |
| 07/2023 | LAUXERA | ORGANOX | UNITED KINGDOM | Medical Devices |
| 07/2023 | EQT PARTNERS / ADIA | DECHRA PHARMACEUTICALS | UNITED KINGDOM | Pharma & Biotech |
| 06/2023 | NOVO NORDISK | BIOCORP | FRANCE | Medical Devices |
REFERENCES
Revenue range: REV 1m EUR - 100m EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Alphacaps by Luxempart are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Target: alphacaps
Acquirer: luxempart
FAQ
What transaction does this page cover?
How does the valuation of Alphacaps compare to benchmarks in the Healthcare & Pharma sector?
What sources support the information on this transaction?
What is mynth?